|
|
serine protease inhibitor WX-671 An orally bioavailable, 3-amidinophenylalanine-derived, second generation serine protease inhibitor prodrug targeting the human urokinase plasminogen activator (uPA) system with potential antineoplastic and antimetastatic activities. After oral administration, serine protease inhibitor WX-671 is converted to the active Nα-(2,4,6-triisopropylphenylsulfonyl)-3-amidino-(L)-phenyla lanine-4-ethoxycarbonylpiperazide (WX-UK1), which inhibits several serine proteases, particularly uPA; inhibition of uPA may result in the inhibition of tumor growth and metastasis. uPA is a serine protease involved in degradation of the extracellular matrix and tumor cell migration and proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Code name: | | WX-671 | | | Chemical structure name: | | N-α-(2,4,6-triisopropylphenyl-sulfonyl)-3-hydroxyamidino-(L )-phenylalanine-4-ethoxycarbonylpiperazide | | |
|
|